Neutral on Dr Lal Pathlabs, target price Rs 1,471: Nomura
The company has started testing in Delhi but it is unlikely to have a positive impact on FY21 earnings, said Nomura.from Markets-Economic Times https://ift.tt/34kC2Gt
The company has started testing in Delhi but it is unlikely to have a positive impact on FY21 earnings, said Nomura.from Markets-Economic Times https://ift.tt/34kC2Gt
Post a Comment